Seroprevalence of IgG Antibodies against Mumps in Bulgarian Children under 18 Years of Age

Yıl 2013, Cilt: 2013 Sayı: 1, 16 - 18, 01.01.2013

Milena Karcheva Galya Gancheva

https://doi.org/10.5152/balkanmedj.2012.108

Öz

Objective: The objective of this study was to determine the prevalence of IgG antibodies against mumps in a representative stratified sample of children under 18 years of age in Pleven district, Bulgaria. Study Design: Cross sectional study. Materials and Methods: A cross-sectional, sero-epidemiologic survey of 132 children aged under 18 years was conducted in Pleven district. They were distributed into two age groups: from 0 to 11 years old (n=80) and from 12 to 18 years old (n=52). An enzyme immunoassay (EIA) was performed for indirect evidence of specific IgG antibodies in the serum. Results: The results showed that 41% of the investigated children were negative in terms of mumps IgG antibodies, 11% had borderline values and the remaining, approximately 48%, were positive. In the group of children aged 0 to 11 years who had received one dose of the mumps vaccine, 50% were negative for mumps IgG antibodies. In the second group of children aged 12 to 18 years who had received two vaccine doses, the percentage of participants negative for mumps IgG antibodies decreased significantly. Conclusion: Our observations emphasise the need to conduct expanded sero-epidemiological investigations of the populations most affected by mumps and to immunise susceptible individuals. Turkish Başlık: 18 Yaş Altı Bulgar Çocuklarda Kabakulak IgG Antikorlarının Seroprevalansı Anahtar Kelimeler: Kabakulak, seroprevalans, immünizasyon Amaç: Bu çalışmanın amacı Bulgaristan Plevne bölgesinde, 18 yaş altı çocukların temsil edici tabakalandırılmış bir örnekleminde, kabakulak IgG antikorlarının prevalansını saptamaktır. Çalışma tasarımı: Kesitsel çalışma. Materyal ve Metot: Plevne bölgesinde 18 yaş altı 132 çocukta kesitsel, sero-epidemiyolojik tarama yapıldı. Çocuklar iki yaş grubuna ayrıldı: 0 ila 11 yaş (n=80) ve 12 ila 18 yaş (n=52). Serumda spesifik IgG antikorlarının indirekt tayini için enzim immunoassay (EIA) yapıldı. Bulgular: Bulgular araştırılan çocukların %41'inde kabakulak IgG antikorlarının negatif olduğunu, %11'inin sınır değere sahip olduğunu ve kalan yaklaşık %48'inin pozitif olduğunu gösterdi. Bir doz kabakulak aşısı yapılmış olan, yaşları 0 ila 11 yıl olan çocuk grubunda %50'sinde kabakulak IgG antikorları negatif idi. İki aşı dozu almış olan, yaşları 12 ila 18 yıl olan ikinci grup çocuklarda kabakulak IgG antikorları negatif olan katılımcıların oranı belirgin olarak azdı. Sonuç: Gözlemlerimiz, çoğu kabakulaktan etkilenmiş olan popülasyonun yaygın sero-epidemiyolojik araştırmasının yapılmasına ve duyarlı kişilerin bağışıklanmasına gereksinimi vurgulamaktadır.

Anahtar Kelimeler

Mumps, seroprevalence, immunisation

Seroprevalence of IgG Antibodies against Mumps in Bulgarian Children under 18 Years of Age

Öz

Kaynakça

• Karcheva M. Survey on efficiency of mass specific immune prophylactics at mumps. Summary of Dissertation. 2010;1-65.
• Amanna IJ, Nichole EC, Mark KS. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007;357:1903-15. [CrossRef]
• Dominguez A, Plans P, Costa J, Torner N, Cardenosa N, Batalla J, et al. Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain:results of a cross-sectional study. Eur J Clin Microbiol Infect Dis 2006;25:310-7. [CrossRef]
• Desgrandchamps D, Schaad UB, Glaus J, Tusch G, Heininger U. Seroprevalence of IgG antibodies against measles, mumps and rubella in Swiss children during the first 16 months of life. Schweizerische Medizinische Wochenschrift 2000;130:1479-86.
• Gürgöze MK, Yilmaz E, Gödekmerdan A, Akça Z, Doğan Y, Akarsu S, et al. Seroprevalence of mumps, varicella and rubella antibodies in children 1-16 years of age in eastern Turkey. Turk J Pediatr 2006;483:185-8.
• Sáenz González MC, Nşñez Mateos JC, Rodrigo Sánchez N, Martín Sánchez AM. Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca. An Esp Pediatr 1992;36:293-7.
• Socan M, Berginc N. High seroprevalence of varicella, measles, mumps, rubella and pertussis antibodies in first-grade medical students. Wien Klin Wochenschr 2008;120:422-6. [CrossRef]
• Odiseev H. Specific immuno prophylactics of mumps with live vaccine-strain, Sofia 6. Summary of Dissertation 1970;1-74.
• Odiseev H. Surveys on mumps in Bulgaria. Summary of Dissertation 1976;1-76.
• Eriksen J, Davidkin I, Kafatos G, Andrews N, Barbara C, Cohen D, et al. Seroepidemiology of mumps in Europe (1996-2008):why do outbreaks occur in highly vaccinated populations? Epidemiol Infect 2012;12:1-16.
• Muhsen Kh, Aboudy Y, Mendelson E, Green MS, Cohen D. Prevalence of mumps antibodies in the Israeli population in relation to mumps vaccination policy and incidence of disease. Epidemiol Infect 2008;136:688-93. [CrossRef]
• Stohrer-Draxl P, Amstad H, Grize L, Gassner M, Takken-Sahli K, Bourquin C, et al. Measles, mumps and rubella:vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96. Schweiz Runsch Med Prax 1999;88:1069-77. Zäch K, Nicoara C, Germann D, Matter L. Age-related seroprevalence of measles, mumps and rubella antibodies in 1996. Schweiz Med Wochenschr 1998;128:649-57.